NCT07272109Not yet recruitingPhase 3
Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes
Active Anti-diabetic Treatment Plus Chemotherapy for Metastatic Pancreatic Cancer Related Diabetes Mellitus (Type 3c)
Source: ClinicalTrials.gov · Last updated 15 Dec 2025
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy of anti-diabetic treatment on improving the overall survival for metastatic pancreatic cancer patients complicated by diabetes receiving gemcitabine and nab-paclitaxel chemotherapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 210 (estimated)
- First submitted
- 26 Nov 2025
- Start date
- 1 Jan 2026
- Primary completion date
- 30 Dec 2027
- Lead sponsor
- Fudan University
- Diseases
- Pancreatic cancer
- NCT number
- NCT07272109
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 210
- From 1 Jan 2026 to the primary completion date, 30 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- • History of other malignancies requiring anti-cancer therapy within 2 years prior to enrollment (except treated Stage I prostate cancer, in situ cervical cancer, in situ breast cancer, etc.);
- Non-primary pancreatic cancer patients;
- Digestive tract inflammation, including biliary tract infection, gastrointestinal infection, pancreatitis, etc.;
- Pregnant or lactating women.
Who the study is looking for
- Ability to understand and the willingness to sign a written informed consent document.
- Age ≥ 18 years and ≤ 80 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Histologically or cytologically confirmed metastatic pancreas adenocarcinoma.
- History of diabetes mellitus, or newly diagnosed diabetes meeting the diagnostic criteria of the American Diabetes Association.
- The expected survival ≥ 3 months.
- Able to comply with study visit schedules and other protocol requirements.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.